Health Care • Medical Specialities
$4.58 ▼ -0.21
(-4.38%)
MKT CAP: $2.43B • VOL: 4.07M
52W L $2 52W H $6
CLOV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.92B | $1.37B | $1.26B |
| YoY Revenue Growth % | +40.3% | +8.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$85.5M | -$45.7M | -$205.3M |
| Operating Margin % | -4.4% | -3.3% | -16.3% |
| Net Income (GAAP) | -$85.5M | -$43.0M | -$213.4M |
| EBITDA (Normalized) | -$83.9M | -$44.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$66.9M | $34.8M | -$144.7M |
| Capital Expenditures (CapEx) | $2.0M | $1.6M | — |
| Free Cash Flow (FCF) | -$69.0M | $33.3M | -$144.7M |
| FCF Margin % | -3.6% | 2.4% | -11.5% |
| Return on Invested Capital (ROIC %) | -29.3% | -24.7% | — |
| Cash & Short-Term Equivalents | $78.3M | $194.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $308.7M | $341.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CLOV.